



Clinicians' Perspectives on the Role of Cefpodoxime-Clavulanate Combination in Respiratory Tract Infection Management: A Cross Sectional Survey

Mishra A et.al; International Journal of Current Pharmaceutical Review and Research 2025; 17(4); 559-566.

- Respiratory infections contribute significantly to global morbidity and mortality, with bacterial infections playing a crucial role in disease burden. Cefpodoxime is used in combination with clavulanic acid to enhance its efficacy against beta-lactamase-producing bacteria.
- A descriptive, questionnaire-based cross-sectional survey was conducted among 709 clinicians from varied specialties who were attending national conferences throughout the country. This survey utilized a pre validated questionnaire comprising of 8 multiple choice questions.
- The survey participants consisted of ENT surgeons (37.79%), Pediatricians (29.47%), and Consulting Physicians (29.33%), and General Physicians (3.41%) comprising the rest. More than half of the respondents (54.18%) prescribe cefpodoxime-clavulanate routinely (Always/frequently) on their clinical practice. Among the RTIs, cefpodoxime-clavulanate is most used in acute otitis media (36.81%) and acute bacterial sinusitis (31.59%) followed by acute tonsillopharyngitis (18.47%), community-acquired pneumonia (12.83%) and other undefined URTIs (0.28%).
- Almost all (92.52%) clinicians rated the effectiveness of cefpodoxime clavulanate as good or excellent. As per their experience, patient adherence was also high, with 67.41% demonstrating excellent compliance.

Cefpodoxime-Clavulanate as a widely used first-line therapy for RTIs, preferred in severe, resistant, and recurrent cases.

